Therapeutic effect of precise radiotherapy combined with gefitinib in the treatment of elderly patients with advanced non - small cell lung cancer / 中国生化药物杂志
Chinese Journal of Biochemical Pharmaceutics
; (6): 219-221, 2017.
Article
de Zh
| WPRIM
| ID: wpr-615769
Bibliothèque responsable:
WPRO
ABSTRACT
Objective To explore the clinical effect of precise radiotherapy combined with gefitinib in the treatment of elderly patients with locally advanced non -small cell lung cancer. Methods 88 cases with locally advanced non small cell lung cancer patients treated from December 2014 to January 2016 in Shanxi Cancer hospital were randomly divided into control group and study group (n=44) by random number table method, the control group received radiotherapy, the study group on precise radiotherapy given gefitinib oral treatment, clinical intervention for 3 months evaluation of clinical efficacy of the two groups, the levels of serum tumor markers (CEA, CA125, CA242) in the two groups were compared before and after the intervention, and the incidence of adverse drug reactions was observed and compared. Results The control rate of the study group and the control group were 90.91% and 72.72% respectively, the difference was statistically significant (P<0.05). After treatment, the levels of CEA, CA125 and CA242 in the two groups were significantly lower than those in the control group (P<0.05). The level of CEA, CA125 and CA242 in the study group was significantly lower than that in the control group (P<0.05), after treatment the study group decreased more significant than the control group (P<0.05). The study group and the control group had adverse adverse reaction rates were 34.14% and 27.27%, and rank sum test the research group VS control group (Z=0.657, P=0.511), there was no significant difference between the two groups. Conclusion Precise radiotherapy combined with gefitinib in the elderly patients with locally advanced NSCLC treatment is a safe treatment method, can effectively improve the clinical efficacy, improve the level of serum tumor markers, it is worthy of clinical application.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Chinese Journal of Biochemical Pharmaceutics
Année:
2017
Type:
Article